Stock Events

Photocure ASA 

kr58.4
17
+kr1.6+2.82% Today

Statistics

Day High
58.6
Day Low
56.2
52W High
71.9
52W Low
40.7
Volume
41,334
Avg. Volume
57,608
Mkt Cap
1.58B
P/E Ratio
323.33
Dividend Yield
-
Dividend
-

Dividends

0%Dividend Yield
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

1NovConfirmed
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
-1.05
-0.51
0.03
0.57
Expected EPS
-0.16
Actual EPS
-0.37

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PHO.OL. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Abbvie
ABBV
Mkt Cap295.34B
AbbVie competes in the bladder cancer space with treatments that could be seen as alternatives to Photocure's diagnostic solutions.
Roche
RHHBY
Mkt Cap191.27B
Roche Holding AG offers a range of oncology treatments, including diagnostics and therapeutics that could compete with Photocure's bladder cancer detection and treatment products.
Bristol-Myers Squibb
BMY
Mkt Cap80.39B
Bristol-Myers Squibb has a portfolio of oncology products that could serve as alternatives to Photocure's offerings, particularly in the bladder cancer segment.
Merck &
MRK
Mkt Cap320.27B
Merck & Co., Inc. provides a variety of cancer treatments, including immunotherapies that could compete with Photocure's bladder cancer solutions.
Pfizer
PFE
Mkt Cap158.95B
Pfizer Inc. has a broad oncology portfolio, including treatments for bladder cancer that could compete with Photocure's products.
Astrazeneca
AZN
Mkt Cap239.79B
AstraZeneca PLC has a strong presence in the oncology market, including treatments that could compete with Photocure's bladder cancer diagnostics and therapeutics.
Novartis
NVS
Mkt Cap236.8B
Novartis AG offers a wide range of cancer treatments, including therapies for bladder cancer that could be seen as competitive to Photocure's products.
Johnson & Johnson
JNJ
Mkt Cap352.53B
Johnson & Johnson, through its Janssen Pharmaceuticals division, develops oncology treatments that could compete with Photocure's bladder cancer solutions.
GSK
GSK
Mkt Cap80.5B
GlaxoSmithKline plc has a portfolio of oncology products, including treatments for bladder cancer that could compete with Photocure's offerings.
Sanofi
SNY
Mkt Cap125.78B
Sanofi offers oncology treatments, including those for bladder cancer, that could serve as alternatives to Photocure's diagnostic and therapeutic products.

About

Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the BeNeLux, Italy, other European Countries, Canada, and the United States. It operates through Commercial Franchise and Development Portfolio segments. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus-induced cervical precancerous lesions. The company has a license agreement with Asieris MediTech Co to develop and commercialize Cevira. It sells its products to pharmaceutical wholesalers, pharmacies, and hospitals through license partners. Photocure ASA was founded in 1993 and is headquartered in Oslo, Norway.
Show more...
CEO
Mr. Daniel Schneider
Employees
102
Country
NO
ISIN
NO0010000045
WKN
000931150

Listings